ETFs Myriad Genetics, Inc.

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2026-10-23 EDT			5-day change	1st Jan Change
5.820 ^USD	+1.04%		+33.79%	-5.37%

10-22	Myriad Genetics Says New Results Show Potential of MRD Detection in Colorectal, Pancreatic Cancers	MT
10-22	Myriad Genetics, Inc. Releases New MONSTAR-SCREEN-3 Data Demonstrating The Potential Of Ultra-Sensitive MRD Detection In Colorectal And Pancreatic Cancers	CI

ETFs positioned on Myriad Genetics, Inc.

Name	YTD change	Weight	AuM
UBS MSCI USA SELECT FACTOR MIX UCITS ETF (HEDGED TO CHF) A-ACC - CHF	+9.39%	-	28 M€
INVESCO S&P SMALLCAP 600 REVENUE ETF - USD	+18.88%	-	2,098 M€
INVESCO S&P SMALLCAP HEALTH CARE ETF - USD	+22.57%	1.56%	184 M€
INVESCO NASDAQ FUTURE GEN 200 ETF - USD	+14.52%	0.55%	23 M€
GLOBAL X GENOMICS & BIOTECHNOLOGY ETF - USD	0.00%	0.48%	87 M€
GLOBAL X GENOMICS & BIOTECHNOLOGY UCITS ETF - USD	+50.02%	0.36%	58 M€
BMO S&P US SMALL CAP INDEX ETF - CAD	+17.10%	0.2%	142 M€
ISHARES RUSSELL 2000 VALUE ETF - USD	+17.54%	0.15%	14,676 M€
VANGUARD S&P SMALL-CAP 600 GROWTH ETF - USD	+14.28%	0.14%	1,134 M€
STATE STREET SPDR S&P BIOTECH ETF - USD	+22.64%	0.14%	10,676 M€
GLOBAL X S&P BIOTECH ETF - AUD	+18.31%	0.13%	35 M€
FIRST TRUST SMALL CAP CORE ALPHADEX FUND ETF - USD	+21.73%	0.13%	1,411 M€
ISHARES S&P SMALL-CAP 600 VALUE ETF - USD	+15.58%	0.1%	8,373 M€
FIRST TRUST MULTI CAP GROWTH ALPHADEX FUND ETF - USD	+8.85%	0.1%	608 M€
STATE STREET SPDR PORTFOLIO S&P 600 SMALL CAP ETF - USD	+14.66%	0.07%	17,332 M€
GOLDMAN SACHS ACTIVEBETA U.S. SMALL CAP EQUITY ETF - USD	+13.98%	0.06%	1,095 M€
FIDELITY ENHANCED SMALL CAP ETF - USD	+19.16%	0.06%	6,480 M€
ISHARES S&P U.S. SMALL-CAP INDEX ETF - CAD	+18.03%	0.05%	75 M€
OVERLAY SHARES SMALL CAP EQUITY ETF - USD	+8.48%	0.05%	37 M€
ISHARES HEALTHCARE INNOVATION UCITS ETF - USD	+23.19%	0.05%	1,260 M€
JPMORGAN MARKET EXPANSION ENHANCED EQUITY ETF - USD	+14.40%	0.05%	2,982 M€
STATE STREET SPDR S&P 600 SMALL CAP VALUE ETF - USD	+15.19%	0.05%	5,092 M€
FIDELITY ENHANCED U.S. ALL-CAP EQUITY ETF - USD	+12.16%	0.05%	18 M€
ISHARES MORNINGSTAR SMALL-CAP ETF - USD	+10.10%	0.04%	292 M€
ISHARES S&P SMALL-CAP ETF - AUD	+8.77%	0.04%	626 M€
FRANKLIN U.S. SMALL CAP MULTIFACTOR INDEX ETF - USD	+13.13%	0.04%	53 M€
INVESCO RAFI US 1500 SMALL-MID ETF - USD	+15.04%	0.04%	2,894 M€
STATE STREET SPDR RUSSELL 2000 U.S. SMALL CAP UCITS ETF - USD	+12.50%	0.04%	5,739 M€
BMO S&P US SMALL CAP INDEX ETF - CAD HEDGED	0.00%	0.04%	27 M€

1 2 3 4 5

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâ€™s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Employees

2,700

Sector

Medical Equipment, Supplies & Distribution

Calendar

11-04 Earnings release - Q3 2026

More about the company